Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| plasma cell | 7 studies | 28% ± 8% | |
| CD16-negative, CD56-bright natural killer cell, human | 5 studies | 18% ± 2% | |
| CD16-positive, CD56-dim natural killer cell, human | 5 studies | 19% ± 3% | |
| epithelial cell | 4 studies | 21% ± 6% | |
| plasmacytoid dendritic cell | 4 studies | 22% ± 2% | |
| non-classical monocyte | 3 studies | 23% ± 5% | |
| natural killer cell | 3 studies | 18% ± 2% | |
| dendritic cell | 3 studies | 27% ± 7% |
Insufficient scRNA-seq data for expression of TAPBPL at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| kidney | 100% | 1632.08 | 89 / 89 | 100% | 45.19 | 897 / 901 |
| thymus | 100% | 2792.75 | 653 / 653 | 100% | 48.98 | 602 / 605 |
| intestine | 100% | 1942.28 | 966 / 966 | 99% | 46.78 | 524 / 527 |
| lung | 100% | 1587.33 | 578 / 578 | 99% | 38.07 | 1143 / 1155 |
| breast | 100% | 1340.54 | 459 / 459 | 99% | 34.56 | 1103 / 1118 |
| stomach | 100% | 1257.52 | 359 / 359 | 99% | 40.85 | 282 / 286 |
| prostate | 100% | 1708.22 | 245 / 245 | 98% | 33.09 | 494 / 502 |
| ovary | 100% | 1156.53 | 180 / 180 | 98% | 50.85 | 423 / 430 |
| pancreas | 99% | 681.84 | 324 / 328 | 99% | 41.41 | 176 / 178 |
| esophagus | 100% | 1142.60 | 1445 / 1445 | 97% | 30.07 | 178 / 183 |
| bladder | 100% | 1562.33 | 21 / 21 | 97% | 37.49 | 489 / 504 |
| liver | 100% | 1033.16 | 226 / 226 | 97% | 28.25 | 392 / 406 |
| uterus | 100% | 1384.06 | 170 / 170 | 96% | 34.70 | 442 / 459 |
| skin | 100% | 879.97 | 1806 / 1809 | 95% | 28.31 | 450 / 472 |
| adrenal gland | 100% | 1246.88 | 258 / 258 | 95% | 28.11 | 218 / 230 |
| brain | 82% | 433.93 | 2165 / 2642 | 97% | 20.28 | 682 / 705 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 39.98 | 29 / 29 |
| spleen | 100% | 2161.51 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 39.16 | 45 / 45 |
| adipose | 100% | 1198.61 | 1203 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 1097.36 | 1332 / 1335 | 0% | 0 | 0 / 0 |
| peripheral blood | 99% | 1882.87 | 919 / 929 | 0% | 0 | 0 / 0 |
| heart | 98% | 987.10 | 845 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 96% | 27.21 | 77 / 80 |
| muscle | 87% | 414.40 | 700 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0002590 | Biological process | negative regulation of antigen processing and presentation of peptide antigen via MHC class I |
| GO_0002502 | Biological process | peptide antigen assembly with MHC class I protein complex |
| GO_0000139 | Cellular component | Golgi membrane |
| GO_0042824 | Cellular component | MHC class I peptide loading complex |
| GO_0005783 | Cellular component | endoplasmic reticulum |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0062061 | Molecular function | TAP complex binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0023024 | Molecular function | MHC class I protein complex binding |
| Gene name | TAPBPL |
| Protein name | Tapasin-related protein (TAPASIN-R) (TAP-binding protein-like) (TAP-binding protein-related protein) (TAPBP-R) (Tapasin-like) TAP binding protein like (TAP binding protein-like, isoform CRA_c) |
| Synonyms | hCG_2039662 |
| Description | FUNCTION: Component of the antigen processing and presentation pathway, which binds to MHC class I coupled with beta2-microglobulin/B2M. Association between TAPBPR and MHC class I occurs in the absence of a functional peptide-loading complex (PLC). . |
| Accessions | ENST00000544021.5 Q9BX59 G3V1T3 ENST00000266556.8 [Q9BX59-1] |
